Status:
COMPLETED
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Tibotec Pharmaceutical Limited
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Purpose: The purpose of this exploratory study is to evaluate phosphoprotein profiling to determine differences in the intracellular actions of interferon or interferon stimulated genes among people ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- To be eligible for this study, subjects must meet the following inclusion criteria:
- Willing and able to provide informed consent
- Males or females age 18 - 65 years
- For women of childbearing potential, negative blood pregnancy test documented within the 24-hour period prior to IFN-α administration
- History of genotype 1 HCV infection previously treated with peginterferon and ribavirin and with a virological response that can be determined from retrospective review of medical records
- A washout period of \>12 weeks between the last dose of prescribed peginterferon and ribavirin and the screening visit
- Exclusion Criteria
- Subjects with any of the following will not be eligible for participation:
- Neutrophil count \<1500 cells/mm3, Hgb \<12 g/dL in women or 13 g/dL in men, or platelet count \<75,000 cells/mm3 at screening
- Serum creatinine level \>1.5 times the upper limit of normal at screening
- Poorly controlled psychiatric illness, as determined by the study physician, which can be exacerbated by interferon therapy
- Infection requiring antibiotics, symptomatic viral infection, inflammatory process requiring therapy, or allergic reactions in the week immediately preceding the inpatient study visit
- Use of medications that affect the immune system (e.g. glucocorticoids, chronic NSAIDs daily) in the week immediately preceding the inpatient study visit
- History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, psoriasis, rheumatoid arthritis)
- Women with ongoing pregnancy or breast-feeding
- History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- History of a seizure disorder or current anticonvulsant use
- History of major organ transplantation with an existing functional graft
- History of thyroid disease poorly controlled on prescribed medications
- History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
Exclusion
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01217359
Start Date
May 1 2010
End Date
August 1 2012
Last Update
November 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina
Chapel Hill, North Carolina, United States, 27599